EMJ GOLD: Pharma news, views and analysis

This content has been funded by Angelini Pharma . In this episode, Isabel sits down with Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, to explore how new science is reshaping brain health and what that means for patients. In the episode, Rafal reflects on his path into neuroscience and explains how Angelini is building its brain health pipeline, with a focus on epilepsy. He discusses...

In Part 3, Hideki Garren, Roche, shares a hopeful vision for slowing, stopping and ultimately preventing multiple sclerosis. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology...

In Part 2, Hideki Garren, Roche, discusses the challenge of measuring MS progression and the importance of better data, imaging and patient insight. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led...

This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients. In Part 1, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. Guest bio Hide...

In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they're working towards in 2026. Speaker bios Dheepa Chari Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are...

As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year's pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women's health, alongside the key threats that could slow progress.  Speaker bios Dheepa Chari Vice President...

This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and pr...

  In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too many women and why embedding sex- and gender-aware science from day one could accelerate fairer, more effective care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice Pr...

In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinical trial exclusion continues to skew the science. Discover why representation isn't just a workforce issue: it's a scientific necessity, and the first barrier we must dismantle to...

This week, Isabel sits down with Carol Pitcher-Towner, Senior Vice President and Head of Development Programmes, Alnylam Pharmaceuticals, to unpack the gender inequities that continue to tarnish modern healthcare. Together, they explore the realities behind unequal outcomes and the steps needed to build a more inclusive future for patients. In Part 1, Carol eveals the personal experiences that mad...

In Part 3, Hanna Svanbäck discusses the future of Alzheimer's care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experie...

In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer's care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive news about prevention.  Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna...

This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer's research. Together, they explore the latest breakthroughs, the challenges ahead and the strategies shaping the future of treatment and prevention. In Part 1 of the conversation, find out about Hanna's journey into neuroscience, her w...

In Part 3 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, talks about his outlook for the future of his field, his views on how the industry and clinicians can collaborate more effectively and the healthcare changes he is most excited about. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Eur...

In Part 2 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business, Medtronic, shares how ECMO has transformed over the decades and explores how clinicians and industry can work together to support the most vulnerable patients in intensive care. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, w...

This week, Isabel is joined by Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, for a deep-dive into the evolution and future of ECMO, innovation in critical care and the realities of leading in the MedTech space. In Part 1 of the interview, Giuseppe talks about what attracted him to the medical device industry, what his day-to-day role involves and...

In Part 2 of this conversation, Robert Stewart, CEO, Theramex, explains how wider society can improve outcomes for women and reflects on the impact of decades of neglect in the field. Speaker bio Robert Stewart is CEO of Theramex, a global pharma company committed to supporting women's health across contraception, fertility, menopause and osteoporosis. With over 30 years of industry experience, he...

The EMJ GOLD podcast returns. To launch the series, Isabel is joined by Robert Stewart, CEO, Theramex – a global pharmaceutical company solely dedicated to women's health. In Part 1 of this discussion, they unpack what inspired Rob's professional focus in this area and the role men can play in championing women's health. Speaker bio Robert Stewart is CEO of Theramex, a global pharma company commit...

Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry d...

How can industry close the screening gap in breast cancer? Find out in this episode, where Dr Joana Reis, Medical Affairs Breast Lead, Radiology, Bayer, explores some of the most significant challenges and opportunities in imaging today. Together, Jade and Joana discuss her initial interest in a career in radiology, the pivotal role of professional societies in accelerating innovation, how AI is s...

Tune in as Dr Daejin Adiboye,  Vice President, Therapeutic Area Head, Solid Tumor Oncology, AbbVie, explores both the evolution of cancer care and his leadership style over the last two decades. Together, Daejin and Jade discuss the lessons from his time in the clinic that shaped who he is today, the move to precision medicine in oncology, his work with the Cancer Support Community in San Francisc...

What is the environmental impact of respiratory illness? Find out in this episode of the EMJ GOLD podcast, where Shish Patel, Medical Director, Chiesi UK, joins Isabel to discuss the rising burden of COPD and the impact of respiratory care on the planet.   Together, the two explore the diagnostic gap in COPD, improving the experience of people living with the disease, balancing health innovation w...

In this week's episode of the EMJ GOLD Podcast, Matt Mortimer Ryan, Senior Global Marketing Manager, Vaccines, GSK , shares his perspective on how understanding patients' emotional drivers can unlock more impactful, insight-led disease awareness campaigns.   Matt joins Isabel to discuss what true patient-centric marketing looks like in practice, how to translate behavioural insights into smarter s...

In this special edition of the EMJ GOLD podcast, Isabel and Jade dive into the latest insights from recent contributors and EMJ's own data to uncover what healthcare professionals really want from medical affairs. They explore the growing challenges of engaging HCPs, question whether there's a gap between what HCPs say they want and what actually captures their attention and look ahead to what the...

This week, the team is joined by Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, to explore how the UK is shaping access to medicine today, and what needs to change in the future. From healthy ageing to the economic cost of respiratory infections, they dive into what the UK is getting right, where it's falling short and why access to medicine matters now more tha...